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Aims:Apoptosis of cardiomyocytes is thought to account for doxorubicin cardiotoxicity as it contributes to loss of
myocardial tissue and contractile dysfunction. Given that high-mobility group box 1 (HMGB1) is a nuclear DNA-
binding protein capable of inhibiting apoptosis, we aimed to clarify the role of HMGB1 in heat shock protein beta
1 (HSPB1) expression during doxorubicin-induced cardiomyopathy.
Methods and results:Mitochondrial damage, cardiomyocyte apoptosis, and cardiac dysfunction after doxorubicin
administrationwere signiﬁcantly attenuated inmicewith cardiac-speciﬁc overexpression ofHMGB1 (HMGB1-Tg)
compared with wild type (WT) -mice. HSPB1 levels after doxorubicin administration were signiﬁcantly higher in
HMGB1-Tg mice than inWT mice. Transfection with HMGB1 increased the expression of HSPB1 at both the pro-
tein and mRNA levels, and HMGB1 inhibited mitochondrial dysfunction and apoptosis after exposure of
cardiomyocytes to doxorubicin. HSPB1 silencing abrogated the inhibitory effect of HMGB1 on cardiomyocyte
apoptosis. Doxorubicin increased the binding of HMGB1 to heat shock factor 2 and enhanced heat shock element
promoter activity. Moreover, HMGB1 overexpression greatly enhanced heat shock element promoter activity.
Silencing of heat shock factor 2 attenuated HMGB1-dependent HSPB1 expression and abrogated the ability of
HMGB1 to suppress cleaved caspase-3 accumulation after doxorubicin stimulation.
Conclusions:We report the ﬁrst in vivo and in vitro evidence that cardiac HMGB1 increases HSPB1 expression and
attenuates cardiomyocyte apoptosis associated with doxorubicin-induced cardiomyopathy. Cardiac HMGB1
increases HSPB1 expression in cardiomyocytes in a heat shock factor 2-dependent manner.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Doxorubicin, an anthracycline derivative, is an anticancer drug
effective against various types of cancer [1,2]. However, the clinical utility
of doxorubicin is limited by its dose-dependent cardiotoxicity, which
causes dilated cardiac dysfunction and congestive heart failure associated
with doxorubicin cardiomyopathy [3]. For example, approximately 4% of
patients treated with doxorubicin present with dominant heart failure
symptoms following administration of a cumulative doxorubicin dosePulmonology, and Nephrology,
hi, Yamagata 990-9585, Japan.
Shishido).
. This is an open access article underof 500–550 mg/m2, with a frequency of approximately 18% for doses of
551–600 mg/m2, and 36% for doses in excess of 600 mg/m2 [4]. The
mechanism responsible for this cardiotoxicity is thought to be related
to cardiomyocyte apoptosis [5,6], which contributes tomyocardial tissue
loss and severe contractile dysfunction [7].
High-mobility group box 1 (HMGB1) is a nuclear non-histone DNA-
binding proteinwith key roles inmaintaining nuclear homeostasis [8,9].
HMGB1 is highly conserved among species and organs, indicating its
critical role in the modulation of cellular functions. Furthermore, the
fact that HMGB1 knockout mice die shortly after birth and exhibit
severe hypoglycemia shows that HMGB1 is essential for survival [10].
Previous study showed that increased HMGB1 expression inhibits apo-
ptosis in various types of cancer cells [11,12]. Our previous studies
showed that cardiac-speciﬁc HMGB1 overexpression plays a key rolethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Survival rate after doxorubicin administration in HMGB-1 Tg mice. Kaplan–Meier
curves showing signiﬁcantly higher survival rate after doxorubicin administration in
HMGB1-Tg mice compared with those in WT mice (n = 15 each). DOX, doxorubicin;
WT, wild-type littermates; HMGB1, high-mobility group box 1; HMGB1-Tg, mice with
cardiac-speciﬁc HMGB1 overexpression.
Table 1
Comparisons of histological and echocardiographic ﬁndings of HMGB1-Tg mice and their
WT counterparts with and without doxorubicin administration.
DOX (−) DOX (+)
WT HMGB1-Tg WT HMGB1-Tg
Histology
Pre-BW (g) 21.9 ± 1.0 23.0 ± 1.0 22.5 ± 1.3 22.5 ± 0.6
Post-BW (g) 20.7 ± 1.5 22.4 ± 0.7 18.2 ± 1.4 ⁎⁎ 18.0 ± 0.4 ⁎⁎
HW (mg) 118.0 ± 8.6 129.8 ± 5.9 94.8 ± 5.1 ⁎⁎ 107.2 ± 4.0 ⁎#
LW (mg) 106.0 ± 5.0 103.2 ± 9.2 146.4 ± 24.6⁎⁎ 113.0 ± 10.9#
HW/TL
(mg/mm)
7.2 ± 1.6 7.6 ± 1.4 5.6 ± 9.2⁎⁎ 6.5 ± 1.2⁎#
LW/TL (mg/mm) 5.5 ± 3.0 5.4 ± 2.5 7.6 ± 1.3⁎⁎ 5.9 ± 5.9⁎#
Echocardiography
HR (beats/min) 514 ± 5 516 ± 10 514 ± 8 514 ± 4
IVSd (mm) 0.74 ± 0.01 0.76 ± 0.01 0.55 ± 0.01 ⁎⁎ 0.64 ± 0.01 ⁎#
PWd (mm) 0.76 ± 0.01 0.76 ± 0.02 0.55 ± 0.01 ⁎⁎ 0.65 ± 0.01 ⁎#
LVEDD (mm) 3.18 ± 0.02 3.15 ± 0.01 3.49 ± 0.02 ⁎⁎ 3.13 ± 0.02 ⁎#
LVESD (mm) 1.43 ± 0.03 1.44 ± 0.02 2.04 ± 0.01⁎⁎ 1.61 ± 0.01⁎#
FS (%) 54.6 ± 0.4 55.3 ± 0.3 44.5 ± 0.1 ⁎⁎ 50.4 ± 0.2 ⁎#
Data are shown as themean± SEM; n=12 each; ⁎ p b 0.05, ⁎⁎ p b 0.01 vs. vehicle treated
WT-mice; # p b 0.05 vs. doxorubicin treated WT-mice.
DOX, doxorubicin; WT, wild-type littermates mice; HMGB1, high-mobility group box 1;
HMGB1-Tg, cardiac-speciﬁc overexpression of HMGB1 mice; BW, body weight; HW,
heart weight; LW, lung weight; TL tibial length; HR, heart rate; IVSd, intraventricular
septum diameter; PWd, posterior wall diameter; LVEDD, left ventricular end-diastolic
diameter; LVESD, left ventricular end-systolic diameter; FS, fractional shortening; FS =
(LVEDD− LVESD) / LVEDD × 100.
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[13,14]. However, the mechanisms underlying the attenuation of car-
diomyocyte dysfunction by cardiac HMGB1 remain largely unknown.
Heat shock protein beta 1 (HSPB1), also known as HSP-27 in
humans, is a member of the small heat shock protein family and is in-
volved in a wide variety of cellular processes. HSPB1 was originally de-
scribed as an intracellular chaperone able to stabilize the actin
cytoskeleton in response to various stresses [15]. Moreover, HMGB1
regulates HSPB1 expression and mitochondrial quality, which are asso-
ciated with cell susceptibility to apoptosis in mouse embryonic ﬁbro-
blasts [16]. However, to the best of our knowledge, the role of cardiac
HMGB1 in regulation of HSPB1 expression and cardiac apoptosis has
not been documented. Therefore, the present study clariﬁes the impact
of cardiac HMGB1 on doxorubicin-induced cardiomyopathy.
2. Materials and methods
The methods/protocols used in the present study are detailed in the
online data supplement.
2.1. Ethics statement
All experimental procedures were performed according to the
animal welfare regulations of Yamagata University School of Medi-
cine; the study protocol was approved by the Animal Subjects Com-
mittee of the university. The investigation conformed to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication, 8th Edition, 2011).
2.2. Neonatal rat cardiomyocyte culture and treatment
Hearts were promptly collected from neonatal rat pups after
euthanasia by decapitation, and primary cultures of neonatal rat
cardiomyocytes were established [13,17,18]. HMGB1 small interfering
RNA (siRNA; siHMGB1), HSPB1 siRNA (siHSPB1), pGEX-HMGB1, heat
shock factor 2 short hairpin RNA (shRNA; shHSF2), and pGL4.41
(luc2P/HSE/Hygro) were transfected into cardiomyocytes by using
GenomOne-Neo (Ishihara Sangyo Kaisha, Osaka, Japan) or Lipofecta-
mine LTX plus (Life Technologies Japan, Tokyo, Japan), according tothe manufacturers' instructions. Neonatal rat cardiomyocytes were
stimulated with 0.5 M doxorubicin (Wako Jyunyaku Kogyo, Osaka,
Japan) for 6 h.
2.3. In vivo experimental design
Eight-to-ten-week-old mice with cardiac-speciﬁc overexpression
of HMGB1 (HMGB1-Tg) [14] and their wild-type (WT) littermates
were injected intraperitoneally with normal saline (10 μL/mg) or a
single dose of doxorubicin (17.5 mg/kg, 10 μL/mg). The mice were
sacriﬁced 7 days after treatment with an intraperitoneal injection
of ketamine (1 g/kg) and xylazine (100 mg/kg), and their hearts
were immediately excised.
2.4. Western blotting
All proteins were extracted from the left ventricle and neonatal
rat cardiomyocytes by homogenization in ice-cold lysis buffer [19].
Mitochondrial and cytosolic proteins were prepared using a mito-
chondrial isolation kit (Thermo Scientiﬁc, Rockford, IL, USA). Co-
immunoprecipitation and immunoblottingwereperformedaspreviously
described [13].
2.5. Real-time reverse transcription polymerase chain reaction
Real-time RT-PCR ampliﬁcation was performed as previously
described [20,21], and gene expression levels were normalized relative
to levels of transcripts that encode glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH). Primers were designed using sequences deposited
in GenBank (HSPB1, NM_031970; GAPDH, NM_017008).
2.6. Transmission electron microscopy and scanning electron microscopy
analysis
Cardiac tissues were ﬁxed in 2.5% glutaraldehyde buffer. Ultrathin
sections (80 nm) were cut on an RMC MTXL ultra microtome [22].
Grids were examined using a transmission electron microscope
(HITACHI H-7100; Hitachi High-Technologies Corporation, Tokyo,
Japan) and scanning electron microscope (HITACHI S-5000S; Hitachi
High-Technologies Corporation).
2.7. Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was visualized in
cardiomyocytes stained with 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolcarbocyanine iodide (JC-1) (Cayman Chemical
Fig. 2.Mitochondrial pathomorphological changes and cardiomyocyte apoptosis after doxorubicin administration in HMGB1-Tg mice. (A) Mitochondrial pathomorphological changes
observed by transmission electron microscopy. Extensive mitochondrial collapse and vacuolization were observed in sections from doxorubicin-treated WT mice but not in doxorubi-
cin-treated HMGB1-Tg mice. Arrows and arrowheads indicate mitochondrial vacuolization and collapse, respectively. Experiments were performed independently at least three times,
and representative ﬁgures are shown. Scale bar = 1 μm. (B) Extensive vacuolization, observed using scanning electron microscopy, was suppressed in doxorubicin-treated HMGB1-Tg
mice compared to that in doxorubicin-treated WT mice. Arrows indicate mitochondrial vacuolation. Scale bar = 125 μm. (C) Caspase-3 cleavage was inhibited in HMGB1-Tg mice.
Bars representmeans± SEM (n= 6 per group); * p b 0.05 and ** p b 0.01, compared to vehicle treatedWT-mice. (D) Cardiomyocyte apoptosis after doxorubicin administration was ex-
tensive inWTmice, but rare inHMGB1-Tgmice. Arrows indicate apoptotic cells. Scale bar= 10 μm. Bars representmean± SEM (n=6mice per group). DOX, doxorubicin;WT,wild-type
littermates; HMGB1, high-mobility group box 1; HMGB1-Tg, mice with cardiac-speciﬁc HMGB1 overexpression; SEM, standard error of the mean.
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Fig. 3. Detection of mitochondrial membrane potential by JC-1 staining after doxorubicin treatment with elevated or suppressed cardiac HMGB1 levels. (A) Mitochondrial membrane
potential after doxorubicin administration signiﬁcantly decreased in neonatal rat cardiomyocytes following HMGB1 silencing. (B) Transfection with HMGB1 partially restored the
doxorubicin-mediated decrease in mitochondrial membrane potential. Bars represent mean ± SEM (n = 4 each); * p b 0.05 and ** p b 0.01 compared to control. DOX, doxorubicin;
HMGB1, high-mobility group box 1; si, small interfering RNA; JC-1, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide; SEM, standard error of the mean.
4 T. Narumi et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 1–12Co, Ann Arbor, MI, USA) using a laser scanningmicroscope (DMI3000B;
Leica, Microsystems, Wetzlar, Germany) [23].
2.8. Echocardiography determination
Transthoracic echocardiography was recorded under anesthesia
following intraperitoneal injection of pentobarbital sodium (35 mg/kg)
with an FFsonic 8900 instrument (Fukuda Denshi Co., Tokyo, Japan)Fig. 4.HMGB1modiﬁed cleaved caspase-3 abundance and cardiomyocyte apoptosis. (A)Cleaved
cardiomyocytes after HMGB1 silencing (n = 5). (B) Cardiomyocyte apoptosis detected by T
cardiomyocytes with HMGB1 silencing. Scale bar = 10 μm (n = 5). (C) Cleaved caspase-3
cardiomyocytes after HMGB1 overexpression (n = 6). (D) HMGB1 overexpression inhibited
Bars represent mean ± SEM; * p b 0.05 and ** p b 0.01 compared to control. DOX, doxorubicin[20,22]. The adequacy of anesthesia was monitored at all times by
assessing of skeletal muscle tone, respiration rate and rhythm, and
response to tail pinch.
2.9. Detection of apoptotic cardiomyocytes
The terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) staining was performed using an In-Situ Cellcaspase-3 levels after doxorubicin administrationwere signiﬁcantly higher inneonatal rat
UNEL staining after doxorubicin administration was signiﬁcantly increased in neonatal
levels after doxorubicin administration were signiﬁcantly suppressed in neonatal rat
cardiomyocyte apoptosis after doxorubicin administration. Scale bar = 10 μm (n = 5).
; HMGB1, high-mobility group box 1; SEM, standard error of the mean.
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USA). For analysis, TUNEL-positive cardiomyocytes were counted in
10 randomly selected ﬁelds per section [7,17].
2.10. Chromatin immunoprecipitation assay
Hela cells were used for our chromatin immunoprecipitation assay.
Hela cells were cultured at 37 °C with 5% CO2 in Dulbecco's modiﬁed
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum,
penicillin (100 U/mL), streptomycin (100 μg/mL), 2 mM L-glutamine,
and 4.5 g/L glucose. Chromatin immunoprecipitation assay with the use
of HMGB1 antibody, followed by PCR analysis of the immunoprecipitated
DNA fragments with primer that amplify the promoter region of HSPB1
gene in Hela cells was performed using Shearing ChIP Kit (Nippon gene
Co., LTD., Tokyo, Japan) and OneDay ChIP Kit (Nippon gene) according
to the manufacturers' instructions.
2.11. Statistical analysis
Continuous data are presented as mean ± standard error of mean
(SEM). Statistical differences among groups were evaluated with one-
way analysis of variance (ANOVA) followed by Bonferroni post hoc
analysis. Cumulative survival rates after administration of doxorubicin
were computed using the Kaplan–Meier method and compared using
the log-rank test. P b 0.05was considered statistically signiﬁcant. All sta-
tistical analyses were performed with a standard statistical program
package (JMP version 10; SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Effect of cardiac HMGB1 on cardiac function in doxorubicin
cardiomyopathy
We examined the role of cardiac HMGB1 in heart failure after doxo-
rubicin administration. Heart weight, ratio of heart weight to tibial
length, intraventricular septum diameter, posterior wall diameter, and
fractional shortening were signiﬁcantly reduced. Left ventricular end-
diastolic diameter, left ventricular end-systolic diameter, lung weight,
and ratio of lung weight to tibial length were signiﬁcantly increased at
one week after administration of doxorubicin (17.5 mg/kg), suggesting
the presence of severe heart failure. However, these changes were
prevented at least partially in HMGB1-Tg mice compared with WT-
mice (Table 1). The survival rate after doxorubicin administration was
signiﬁcantly higher in HMGB1-Tg mice than in WT mice (Fig. 1).
3.2. Anti-apoptotic effect of HMGB1 on the heart after doxorubicin
administration
Sincemitochondrial disintegration is an early feature of doxorubicin-
induced apoptosis, we evaluated mitochondrial morphology and
caspase-3 cleavage, and performed TUNEL staining. Mitochondrial
pathomorphological changes were observed by transmission electron
microscopy (Fig. 2A) and by scanning electron microscopy (Fig. 2B) at
one week after administration of doxorubicin. Extensive mitochondrial
collapse and vacuolization were suppressed in doxorubicin-treated
HMGB1-TG mice compared with doxorubicin-treated WT mice. Levels
of cleaved caspase-3 were signiﬁcantly lower in HMGB1-Tg mice than
in WT mice after doxorubicin administration (Fig. 2C). Furthermore,Fig. 5. Intrinsic mitochondrial apoptotic pathway in vivo. (A) Following doxorubicin admini
means ± SEM (n = 6 per group); * p b 0.05 and ** p b 0.01 compared to WT mice without d
mRNA abundance in WT mice. Levels of HSPB1mRNAs after doxorubicin administration wer
(n=6 per group); * p b 0.05 and ** p b 0.01 compared toWTmice without doxorubicin admin
was prevented in HMGB1-Tg mice. Doxorubicin administration increased the abundance of c
abundance of Cox 4 prior to statistical analysis. Bars represent means ± SEM (n= 6 per grou
DOX, doxorubicin; WT, wild-type littermates; HMGB1, high-mobility group box 1; HMGB1-Tg
activator of caspase; Cox 4, cytochrome C oxidase subunit 4; SEM, standard error of the mean.cardiomyocyte apoptosis was reduced after doxorubicin administration
in HMGB1-Tg mice as compared to that in WT mice (Figs. 2D and Sup-
plemental Fig. I).
3.3. Effect of cardiac HMGB1 on mitochondrial membrane potential
To establish whether HMGB1 protects from doxorubicin-induced
mitochondrial dysfunction,we used the JC-1 dye to assessmitochondri-
al membrane potential in neonatal rat cardiomyocytes before and after
treatment with 0.5 M doxorubicin for 3 h. Doxorubicin decreased the
ratio of red ﬂuorescent signal (derived from aggregated dye) to green
ﬂuorescent signal (derived from the monomeric dye), implying de-
creased mitochondrial membrane potential after doxorubicin adminis-
tration. HMGB1 silencing signiﬁcantly decreased the JC-1 aggregate/
monomer ratio after doxorubicin administration (Fig. 3A). In contrast,
HMGB1 transfection prevented the decrease in the JC-1 aggregate/
monomer ratio following doxorubicin administration (Fig. 3B), suggest-
ing that HMGB1 is required for maintainingmitochondrial integrity fol-
lowing the exposure of cardiomyocytes to doxorubicin.
3.4. Impact of HMGB1 on cardiomyocyte apoptosis
To conﬁrm the importance of cardiac HMGB1 in controlling apopto-
sis in cultured cardiomyocytes, cleaved caspase-3 levels and apoptosis
were evaluated in cardiomyocyte after 0.5 M doxorubicin administra-
tion for 6 h. We observed that doxorubicin signiﬁcantly increased
the abundance of cleaved caspase-3 and cardiomyocyte apoptosis.
Moreover, siRNA-mediated HMGB1 silencing in doxorubicin-treated
cardiomyocytes signiﬁcantly increased cleaved caspase-3 levels and
cardiomyocyte apoptosis (Figs. 4A and B). Conversely, HMGB1 transfec-
tion signiﬁcantly attenuated cleaved caspase-3 expression and apopto-
sis, compared with control vector transfection, after doxorubicin
administration (Figs. 4C and D). These results indicate that HMGB1
attenuates mitochondrial dysfunction and cardiomyocyte apoptosis
induced by doxorubicin administration.
3.5. Effect of HMGB1 on cardiac HSPB1 expression after doxorubicin
administration
Recently, an association betweenHMGB1 andHSPB1 expressionwas
reported [16,24], and therefore, we investigated whether HMGB1 could
increaseHSPB1 expression in theheart after doxorubicin administration
(17.5 mg/kg). We observed that doxorubicin signiﬁcantly increased
both the levels of mRNA and protein of HSPB1 in the heart; however
the increases were higher in HMGB1-Tg mice than in WT mice
(Figs. 5A and B). The mitochondrial protein second mitochondria-
derived activator of caspase (Smac) potentiates certain forms of apopto-
sis [25], and HSPB1 regulates the release of Smac from themitochondria
into the cytosol during apoptosis [26]. Therefore, we assessed the effect
of doxorubicin on Smac localization in the heart. Less Smacwas released
from the mitochondria in HMGB1-Tg mice than in WT mice following
doxorubicin administration (Fig. 5C). To evaluate the role of extracellu-
larHMGB1,wemeasured the serum levels of HMGB1, and observed that
HMGB1 concentrations were similarly increased after doxorubicin
treatment in HMGB1-Tg mice and WT mice (Supplemental Fig. II).
These results suggested that intracellular HMGB1 increased HSPB1
expression and attenuated cardiac apoptosis after doxorubicin
administration.stration, HSPB1 levels were higher in HMGB1-Tg mice than in WT-mice. Bars represent
oxorubicin administration. (B) Doxorubicin administration signiﬁcantly increased HSPB1
e signiﬁcantly higher in HMGB1-Tg mice than in WT mice. Bars represent means ± SEM
istration. (C) Doxorubicin-induced release of Smac from themitochondria into the cytosol
ytosolic Smac in WT mice. The abundance of mitochondrial Smac was normalized to the
p); * p b 0.05 and ** p b 0.01 compared to WT mice without doxorubicin administration.
, mice with cardiac-speciﬁc HMGB1 overexpression; Smac, Second mitochondria-derived
7T. Narumi et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 1–12
8 T. Narumi et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 1–12
9T. Narumi et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 1–123.6. Effect of HMGB1 on HSPB1 expression in neonatal rat cardiomyocytes
Several studies have shown that cellular levels of HMGB1 are altered
by ischemia/reperfusion, infarction, and reactive oxygen species
[27–29], we assessed HMGB1 expression levels upon doxorubicin
administration. Doxorubicin signiﬁcantly increased HMGB1 levels
in vivo. However, the protein content was signiﬁcantly higher in
HMGB1-Tg mice compared toWT mice (Fig. 6A). Next, we investigated
the effect of cardiac HMGB1 on HSP-expression after doxorubicin ad-
ministration in vitro, and observed that doxorubicin signiﬁcantly
increased the expression levels of HSP-60, HSP-70, and HSPB1
(Figs. 6B and C). Both HSPB1 protein and mRNA levels were signiﬁ-
cantly higher in neonatal rat cardiomyocytes that overexpressed
HMGB1 than in those with normal levels of HMGB1 following doxo-
rubicin administration (Figs. 6B and Supplemental Fig. IIIA). On the
contrary, HSPB1 protein levels after doxorubicin administration
were lower in neonatal rat cardiomyocytes in which HMGB1 was
silenced than in doxorubicin-treated cells with normal levels of
HMGB1 (Fig. 6C). However, there was no marked difference in the
levels of HSP-60 or HSP-70 and HSP-60 or HSP-70 after doxorubicin
administration in cardiomyocytes with altered levels of HMGB1
(Figs. 6B, C and Supplemental Fig. IIIB and C).
3.7. Contribution of HSPB1 to the anti-apoptotic effect of HMGB1 in
cardiomyocytes
Given our demonstration that HMGB1 increased HSPB1 protein and
mRNA levels, we next investigated the association between the
HMGB1-mediated anti-apoptotic effect and HSPB1 expression at the
protein and mRNA levels. siRNA-mediated HSPB1 silencing increased
cleaved caspase-3 levels after doxorubicin administration (Supplemen-
tal Fig. IV). Importantly, co-transfection of siHSPB1 with vector
encoding HMGB1 abrogated the ability of HMGB1 to suppress cleaved
caspase-3 accumulation, suggesting that the ability of HMGB1 to pro-
mote HSPB1 expression is associated with inhibition of doxorubicin-
mediated apoptosis (Fig. 6D).
3.8. HMGB1-mediated heat shock factor transcriptional activity and HSPB1
promoter activity after doxorubicin administration
Since HSP gene expression is regulated by heat shock factors (HSFs)
[30], we evaluated the association between HMGB1 and HSFs. Heat
shock element (HSE) promoter activity increased upon 0.5M doxorubi-
cin stimulation for 1 h. Moreover, HMGB1 overexpression enhanced
HSE promoter activity compared to empty vector transfection
(Fig. 7A). To examine potential HSF-HMGB1 interaction, we performed
immunoprecipitation experiments. Doxorubicin stimulation increased
protein-to-protein binding of HMGB1 with HSF2 (Figs. 7B and C), but
not HSF 1 or HSF 4 (Supplemental Fig. V), indicating an increase in
HSF2–HMGB1 interaction in response to doxorubicin treatment in
cardiomyocytes.
To conﬁrm the impact of HSF2 on the regulation of HMGB1-
mediated HSPB1 expression, HSPB1 expression after doxorubicin stim-
ulation was assessed upon transfection with shHSF2 (Supplemental
Fig. VI). Co-transfection with shHSF2 and pGEX-HMGB1 attenuated
HMGB1-mediated HSPB1 expression compared to control shRNA trans-
fection (Fig. 7D). Moreover, the ability of HMGB1 to suppress the accu-
mulation of cleaved caspase-3 was abrogated by silencing HSF2
(Fig. 7E). Finally, we examined HMGB1 binding to the HSPB1 promoter,Fig. 6. Role of HSPB1 expression in the HMGB1-dependent anti-apoptotic effect. (A) Doxorubici
(n=6 per group). (B) HSPB1 expression, but not that of HSP-60 or HSP-70, was higher in neon
cardiomyocytes decreasedHSPB1 abundance. (D) Co-transfectionwith siHSPB1 and pGEX-HMG
lation. Bars representmean± SEM (n=4–6 per group) * p b 0.05 and ** p b 0.01 compared to c
doxorubicin; HMGB1, high-mobility group box 1; HSP, heat shock protein; HSPB1, heat shockusing a ChIP assay with the use of HMGB1 antibody, followed by PCR
analysis of the immunoprecipitated DNA fragments with primer that
amplify the promoter region of HSPB1 gene. The result of this experi-
ment, shown in Fig. 7F, indicated that doxorubicin administration sig-
niﬁcantly increased HMGB1 binding to promoter lesion of HSPB1.4. Discussion
The present study demonstrated the critical role of cardiac HMGB1
in cardiomyocyte apoptosis and mitochondrial dysfunction associated
with the pathogenesis of doxorubicin cardiomyopathy. The survival
rate after administration of doxorubicin was signiﬁcantly higher, and
the mitochondrial damage was signiﬁcantly lower, in HMGB1-Tg mice
than in theirWT counterparts. CardiacHMGB1 increasedHSPB1 expres-
sion and suppressed apoptosis after doxorubicin administration both
in vivo and in vitro. HSPB1 expression was regulated by HMGB1 and
HSF2 after doxorubicin stimulation.
The mechanism of pathogenesis of doxorubicin-induced cardiomy-
opathy is thought to relate to cardiomyocyte apoptosis. Prevention of
apoptosis might be a therapeutic target for the preservation of cardiac
function. The present study showed that levels of HSPB1 mRNA and
HSPB1 protein after doxorubicin administration were signiﬁcantly
higher in both HMGB1-transfected cardiomyocytes and HMGB1-Tg
mice than in the cardiomyocytes and mice with normal levels of
HMGB1, and that HMGB1 overexpression suppressed caspase-3 activa-
tion and the number of apoptotic cardiomyocytes after doxorubicin
treatment. In contrast, HMGB1-mediated suppression of caspase-3
cleavage was signiﬁcantly diminished by co-transfection with siHSPB1.
We also showed that after doxorubicin administration, the survival rate
of HMGB1-Tg mice was signiﬁcantly higher than that of WT mice. This
ﬁnding supported the role of cardiac HMGB1 in preventing
doxorubicin-induced cardiomyopathy.
Since HSPB1 is known to prevent caspase activation [15,26], loss of
HSPB1 results in mitochondrial fragmentation with decreased aerobic
respiration [16,24]. Furthermore, loss of HSPB1 decreasesmitochondrial
membrane potential, induces Smac release from mitochondria, and ac-
tivates caspase-3 [26]. In the present study, we observed extensive mi-
tochondrial damage and vacuolization in doxorubicin-treatedWTmice,
but not in HMGB1-Tg mice. To the best of our knowledge, we showed,
for the ﬁrst time, that mitochondrial membrane potential was restored
in neonatal rat cardiomyocytes that overexpressHMGB1, but not in oth-
erwise comparable cells in which HMGB1 expression is silenced. More-
over, less Smac was released from themitochondria of HMGB1-Tg mice
than WT mice. These ﬁndings indicated that cardiac HMGB1 overex-
pression suppressesmitochondrial dysfunction and cardiomyocyte apo-
ptosis by regulating the HSPB1 expression in cardiomyocytes (Fig. 8).
The 215-amino-acid protein HMGB1,whichwas identiﬁed as a chro-
mosomal protein with important structural functions in chromatin or-
ganization, is ubiquitously expressed in all vertebrate nuclei [4,8,31].
HMGB1 binds to double-stranded DNA, and its interaction with other
DNA-binding proteins facilitates chromatin bending [31,32]. This archi-
tectural function facilitates the binding of several transcriptional factors.
The molecular mechanisms underlying the anti-apoptotic effect of
HMGB1 are still unclear. However, HSF2 reportedly binds to the
HSPB1 promoter in Jurkat cells [33]. Our study showed that HMGB1
overexpression enhanced HSE promoter activity, unlike transfection of
an empty vector. Moreover, doxorubicin stimulation enhanced binding
of HSF2 and HMGB1. Silencing HSF2 abolished the anti-apoptotic effect
of HMGB1 overexpression after doxorubicin stimulation. Doxorubicinn administration signiﬁcantly increased HMGB1 abundance. Bars representmeans± SEM
atal rat cardiomyocytes with HMGB1 overexpression. (C) HMGB1 silencing in neonatal rat
B1 attenuated the ability of HMGB1 overexpression to prevent cleaved caspase-3 accumu-
ontrol; # p b 0.05 and ## p b 0.01 compared to the control treatedwith doxorubicin. DOX,
protein binding protein 1; si, small interfering RNA; SEM, standard error of the mean.
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Fig. 8. Proposed mechanism for cardiac HMGB1-mediated attenuation of cardiomyocyte apoptosis and mitochondrial damage after exposure to doxorubicin. Cardiac HMGB1 increased
HSPB1 expression and suppressed cardiomyocyte apoptosis after doxorubicin administration both in vivo and in vitro. HSPB1 expression was regulated by HMGB1 and HSF2 after doxo-
rubicin stimulation. HMGB1, high-mobility group box 1; HSF2, heat shock factor 2; HSPB1, heat shock protein beta 1.
11T. Narumi et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 1–12stimulation also increased in HMGB1 binding to promoter lesion of
HSPB1. Taken together, cardiac HMGB1 increases HSPB1 expression in
cardiomyocytes in an HSF2-dependent manner (Fig. 8). Although the
mechanisms bywhich doxorubicin affects HMGB1 andHSF2 association
have not been elucidate yet, we showed that doxorubicin increased
HMGB1 expression in the heart. Therefore, it is also suspected that in-
creased expression levels of HMGB1 enhanced the binding to HSF2
and affected HSPB1 expressions in the heart after doxorubicin
expressions.
In conclusion, we report the ﬁrst in vivo and in vitro evidence that
cardiac HMGB1 attenuates mitochondrial dysfunction and cardiomyo-
cyte apoptosis associated with the pathogenesis of doxorubicin-
induced cardiomyopathy. These resultsmay provide a novel therapeutic
approach to combat doxorubicin-induced cardiomyopathy.
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